🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We were honored to have our team present our preclinical research supporting our MagSense® imaging agent for the detection of ovarian cancer at the #AACRovc23 in Boston this weekend. Learn more and reivew the poster: 👉 bit.ly/3ZMgJKy #ovariancancer #cancerdetection

🎉 Exciting News: Imagion successfully closes Phase 1 Study for MagSense® HER2 Imaging Agent and the preliminary performance results are in! 🔍 Learn more about this groundbreaking achievement: bit.ly/45xf9xv #MagSense #HER2 #CancerDetection #MolecularMRI $IBX

🎗️💓 Early detection saves lives! In honor of #BreastCancerAwarenessMonth this October, our team is sharing personal stories that drive us to make a difference in cancer detection. 🔬 Empower yourself with knowledge and read stories here: 💻 bit.ly/3rXLsIa #PinkOctober

🎥 A video message from Imagion’s CEO, Isaac Bright - addressing the upcoming 2023 EGM Resolutions. Watch here: ▶️ bit.ly/3tKWjG5 $IBX #EGM #InvestorRelations

@Imagionbio CEO, Isaac Bright, presents our latest investor presentation at the Let's Share Cafe Hidden Gems webinar last week. Catch the webinar with Q&A session here 🎥: bit.ly/45GalWM $IBX #InvestorUpdate #innovation #molecularMRI

🌸 We stand in the fight against breast cancer! Explore helpful early detection resources and read up on our team's inspiring stories 💕 💪 Together, we can make a difference. Learn more > 💻 bit.ly/48ZIVhg #BreastCancerAwareness #PinkOctober #EarlyDetection $IBX

📰 We have released our Quarterly Activity Report and Appendix 4C for the period ending on 30 September 2023. Read the full announcement: bit.ly/45VoAHp $IBX #ASX #MolecularMRI

🎥 Learn about the latest developments at Imagion Biosystems' in this recording from our EGM on 13 November 2023. This event featured insights into our MagSense platform and addressed critical resolutions to be voted on by shareholders. Watch here: ▶️ bit.ly/3QXTMl6 $IBX

Exciting news! 🌟 Tomorrow at 7 am CST, Imagion presents groundbreaking data from our IBI10103 Phase I Study demonstrating the safety and clinical feasibility of Molecular MRI with #MagSense HER2 Imaging Agentat #SABCS23. Request the data: bit.ly/47KhjM3 #Innovation $IBX

🌟Latest study on MagSense HER2 Imaging Agent for breast cancer as an MRI adjunct shows it is safe and effective in distinguishing metastatic breast cancer. Blinded radiologists identified suspicious lymph nodes; no safety issues in 13 patients. More: bit.ly/3RadEQI $IBX

[VIDEO] Following our announcement last week, CEO Dr. Isaac Bright shares Imagion's scientific presentation from SABCS, providing intricate insights into the Phase I Study conducted with #MagSense® HER2 Imaging Agent. Watch HERE ▶️ bit.ly/3GC3J1B $IBX #CancerResearch

📰 We have released our Quarterly Activity Report and Appendix 4C for the period ending on 31 December 2023. Read the full announcement: bit.ly/48VvnTD $IBX

We're very pleased to welcome Brett Mitchell to Imagion Biosystems as a Non-Executive Director. With his wealth of experience in capital markets and the #ASX, we expect Brett will have a significantly positive impact. Welcome aboard, Brett > bit.ly/4clUcJN $IBX

📢 Join our upcoming investor webinar on August 15 at 10am AEST! We'll outline the proposed EGM resolutions, share updates on our #MagSense technology, and discuss our strategic direction. Plus, participate in our live Q&A. Register now: vistra.zoom.us/webinar/regist… $IBX #IBX

📢 Exciting corporate updates! 🔹 IND filing for HER2 Phase 2 Study set for mid-2025 🔹 $3M raise led by CPS Capital closes Dec 🔹 Welcoming Dr. Susan Harvey as Medical Affairs Advisor 🔹 Investor webinar on Nov 27, 9:00 am AEDT Full update 👉imagionbiosystems.com/news/ind-for-m… $IBX

We’re in Chicago for #RSNA24 from Dec. 2-4! Join us and imaging professionals to discover innovations like #MagSense that are driving healthcare forward. Let us know if you’ll be there. 📍 Learn more about the meeting:  lnkd.in/d7b2bB5 #Radiology #HealthcareInnovation

At our recent EGM, Imagion Biosystems shareholders approved a $3M capital raise to support our IND filing — an essential step toward advancing our #MagSense imaging agent technology. We sincerely thank our shareholders for their trust and continued support! $IBX #CancerDetection #EGM

We’re honored to be featured in Stockhead’s latest article, highlighting Imagion Biosystems as one of the ASX-listed cancer-fighting stocks with strong investment potential. 🗞️ Read more: stockhead.com.au/health/bargain… $IBX #CancerDiagnostics #ASXnews